相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
Chee Khoon Lee et al.
CLINICAL CANCER RESEARCH (2012)
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
Birgit Geoerger et al.
EUROPEAN JOURNAL OF CANCER (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors
Sheri L. Spunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile
Beatrice T. Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
Jann N. Sarkaria et al.
CLINICAL CANCER RESEARCH (2010)
mToR signaling and drug development in cancer
Janet Dancey
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis
Erwan Pencreach et al.
CLINICAL CANCER RESEARCH (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Brain tumor imaging in clinical trials
J. W. Henson et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2008)
Shortening the timeline of pediatric phase I trials: The rolling six design
Jeffrey M. Skolnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
Anne-Christine Piguet et al.
JOURNAL OF HEPATOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2008)
Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo
J. I. Johnsen et al.
ONCOGENE (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan
Anshul Gupta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
CCl-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling
Xiaolin Wan et al.
NEOPLASIA (2006)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma
XL Wan et al.
CANCER RESEARCH (2005)
Regulation of cap-dependent translation by eIF4E inhibitory proteins
JD Richter et al.
NATURE (2005)
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
WH Mondesire et al.
CLINICAL CANCER RESEARCH (2004)
Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation
S Mateo-Lozano et al.
ONCOGENE (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
